Literature DB >> 36066579

Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis.

Kosuke Ebina1,2, Yuki Etani3, Hideki Tsuboi4, Yoshio Nagayama5, Masafumi Kashii6, Akira Miyama7, Yasuo Kunugiza8, Makoto Hirao9, Gensuke Okamura4, Takaaki Noguchi9, Kenji Takami3, Atsushi Goshima3, Taihei Miura3, Yuji Fukuda3, Takuya Kurihara3, Seiji Okada3, Ken Nakata10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36066579     DOI： 10.1007/s00198-022-06545-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   5.071


× No keyword cloud information.
  4 in total

1.  Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.

Authors:  Akimitsu Miyauchi; Etsuro Hamaya; Wenjing Yang; Kiyoshi Nishi; Cesar Libanati; Cae Tolman; Junichiro Shimauchi
Journal:  J Bone Miner Metab       Date:  2020-10-15       Impact factor: 2.626

2.  Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.

Authors:  Kosuke Ebina; Makoto Hirao; Hideki Tsuboi; Yoshio Nagayama; Masafumi Kashii; Shoichi Kaneshiro; Akira Miyama; Hiroyuki Nakaya; Yasuo Kunugiza; Gensuke Okamura; Yuki Etani; Kenji Takami; Atsushi Goshima; Ken Nakata
Journal:  Bone       Date:  2020-08-08       Impact factor: 4.398

3.  Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment.

Authors:  A Tominaga; K Wada; K Okazaki; H Nishi; Y Terayama; Y Kodama; Y Kato
Journal:  Osteoporos Int       Date:  2022-01-21       Impact factor: 4.507

4.  Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary.

Authors:  Hajime Orimo; Toshitaka Nakamura; Takayuki Hosoi; Masayuki Iki; Kazuhiro Uenishi; Naoto Endo; Hiroaki Ohta; Masataka Shiraki; Toshitsugu Sugimoto; Takao Suzuki; Satoshi Soen; Yoshiki Nishizawa; Hiroshi Hagino; Masao Fukunaga; Saeko Fujiwara
Journal:  Arch Osteoporos       Date:  2012       Impact factor: 2.617
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.